Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Share-based Compensation (2018 - 2025)

TransMedics (TMDX) has 8 years of Share-based Compensation data on record, last reported at $9.4 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 12.74% year-over-year to $9.4 million; the TTM value through Dec 2025 reached $36.9 million, up 10.95%, while the annual FY2025 figure was $36.9 million, 10.95% up from the prior year.
  • Share-based Compensation reached $9.4 million in Q4 2025 per TMDX's latest filing, up from $9.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $10.8 million in Q4 2024 and bottomed at $1.1 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $5.4 million, with a median of $5.1 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: soared 188.83% in 2021, then decreased 12.74% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $2.0 million in 2021, then surged by 50.68% to $3.0 million in 2022, then surged by 91.37% to $5.7 million in 2023, then surged by 88.1% to $10.8 million in 2024, then fell by 12.74% to $9.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $9.4 million in Q4 2025, $9.1 million in Q3 2025, and $9.4 million in Q2 2025.